ELV

AI Research

ELV CMS Medicare Advantage Sanctions → 2026 EPS Guide ≥$25.50 Despite Regulatory Headwinds

Elevance Health faces CMS sanctions on its Medicare Advantage plans amid broader industry scrutiny of coverage denials and utilization management practices affecting millions of enrollees. Despite near-term headwinds, management issued 2026 EPS guidance of at least $25.50, signaling confidence in its diversified health insurance portfolio and cost management initiatives. Mizuho maintained its Buy rating but lowered its price target to $350, reflecting regulatory uncertainty and potential margin compression risks in the Medicare Advantage segment.